EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

Alba Aragón-Navas, Maria Jesus Rodrigo, Inés Munuera, David García-Herranz, Manuel Subías, Pilar Villacampa, Julián García-Feijoo, Luis Pablo, Elena Garcia-Martin, Rocio Herrero-Vanrell, Irene Bravo-Osuna iD

Drug Delivery and Translational Research · 2025

DOI: 10.1007/s13346-024-01702-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Alba Aragón-Navas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Techn…. Hauptthemen laut MEDLINE: Glaucoma, Neuroprotective Agents, Dexamethasone, Polyglycolic Acid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Universidad Complutense de Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This work focused on the co-encapsulation and simultaneous co-delivery of three different neuroprotective drugs in PLGA (poly(lactic-co-glycolic acid) microspheres for the treatment of glaucoma. For formulation optimization, dexamethasone (anti-inflammatory) and ursodeoxycholic acid (anti-apoptotic) were co-loaded by the solid-in-oil-in-water emulsion solvent extraction-evaporation technique as a first step. The incorporation of a water-soluble co-solvent (ethanol) and different amounts of dexamethasone resulted critical for the encapsulation of the neuroprotective agents and their initial release. The optimized formulation was obtained with 60 mg of dexamethasone and using an 80:20 dichloromethane:ethanol ratio. In the second step in the microencapsulation process, the incorporation of the glial cell line-derived neurotrophic factor (GDNF) was performed. The final prototype showed encapsulation efficiencies for each component above 50% with suitable properties for long-term application for at least 3 months. Physicochemical studies were performed by SEM, TEM, DSC, XRD, and gas chromatography. The evaluation of the kinetic release by the Gallagher-Corrigan analysis with Gorrasi correction helped to understand the influence of the co-microencapsulation on the delivery of the different actives from the optimized formulation. The final prototype was tested in a chronic glaucoma animal model. Rats received two intravitreal injections of the neuroprotective treatment within a 24-week follow-up study. The proposed formulation improved retinal ganglion cell (RGC) functionality examined by electroretinography. Also, it was able to maintain a neuroretinal thickness similar to that of healthy animals scanned by in vivo optical coherence tomography, and a higher RGC count on histology compared to glaucomatous animals at the end of the study. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlaucomaNeuroprotective AgentsDexamethasonePolyglycolic AcidLactic AcidAnimalsPolylactic Acid-Polyglycolic Acid CopolymerMicrospheresDisease Models, AnimalRatsGlial Cell Line-Derived Neurotrophic FactorMaleDrug Liberation

Stichwörter der Autor:innen

Co-deliveryGlaucoma animal modelMicrospheresNeuroprotectionPoly lactic-co-glycolic acid (PLGA)Retinal neurodegenerative diseases

Substanzen

Polylactic Acid-Polyglycolic Acid CopolymerNeuroprotective AgentsDexamethasonePolyglycolic AcidLactic AcidGlial Cell Line-Derived Neurotrophic Factor

Autor:innen und Institutionen

  • Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid,…
  • Health Research Institute, San Carlos Clinical Hospital (IdISSC), Madrid, Spain.
  • National Ocular Research Network RD21/0002/0050. RICORS Red de Enfermedades Inflamatorias (RD21/0002), Carlos III Health Institute, Madrid, Spain.
  • Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.
  • Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, Zaragoza, Spain.
  • Biotech Vision, Instituto Oftalmologico Quiron, Zaragoza, Spain.

ORCID-Profile: Irene Bravo-Osuna

Förderung

  • Ministerio de Ciencia e Innovación
  • Universidad Complutense de Madrid

Zitieren

APA

Aragón-Navas, A., Rodrigo, M. J., Munuera, I., García-Herranz, D., Subías, M., Villacampa, P., García-Feijoo, J., Pablo, L., Garcia-Martin, E., Herrero-Vanrell, R., & Bravo-Osuna, I. (2025). Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01702-x

Vancouver

Aragón-Navas A, Rodrigo MJ, Munuera I, García-Herranz D, Subías M, Villacampa P, et al. Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01702-x

BibTeX
@article{AragnNavas2025,
  author = {Aragón-Navas, Alba and Rodrigo, Maria Jesus and Munuera, Inés and García-Herranz, David and Subías, Manuel and Villacampa, Pilar and García-Feijoo, Julián and Pablo, Luis and Garcia-Martin, Elena and Herrero-Vanrell, Rocio and Bravo-Osuna, Irene},
  title = {Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model},
  journal = {Drug Delivery and Translational Research},
  year = {2025},
  doi = {10.1007/s13346-024-01702-x}
}
Kostenlos starten →